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Abstract
Kidney transplantation (KTx) represents the best available treatment for patientswith end-stage renal disease. Still, full beneﬁts
of KTx are undermined byacute rejection (AR). The diagnosis of ARultimately relies on transplant needle biopsy. However, such
an invasive procedure is associated with a signiﬁcant risk of complications and is limited by sampling error and interobserver
variability. In the present review, we summarize the current literature about non-invasive approaches for the diagnosis of AR in
kidney transplant recipients (KTRs), including in vivo imaging, gene expression proﬁling and omics analyses of blood and urine
samples. Most imaging techniques, like contrast-enhanced ultrasound andmagnetic resonance, exploit the fact that bloodﬂow
is signiﬁcantly lowered in case of AR-induced inﬂammation. In addition, AR-associated recruitment of activated leukocytes
may be detectable by 18F-ﬂuoro-deoxy-glucose positron emission tomography. In parallel, urine biomarkers, including CXCL9/
CXCL10 or a three-gene signature of CD3ε, IP-10 and 18S RNA levels, have been identiﬁed. None of these approaches has been
adopted yet in the clinical follow-up of KTRs, but standardization of procedures may help assess reproducibility and compare
diagnostic yields in large prospective multicentric trials.
Key words: 18FDG-PET/CT, acute rejection, kidney biopsy, kidney transplantation, magnetic resonance imaging,
ultrasonography
Introduction
Kidney transplantation (KTx) represents the best available treat-
ment for patients with end-stage renal disease. Each year, 3.500
kidney transplants are performed in the EuroTransplant zone
(www.eurotransplant.org). Still, full beneﬁts of KTx are regret-
tably undermined by acute rejection (AR), which may be cellular
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or antibody-mediated [1]. AR may affect all kidney transplant re-
cipients (KTRs) throughout their lifetime, independent of age or
gender [2]. Furthermore, subclinical AR affects 10–30% of KTRs
within the ﬁrst year following KTx and is an early predictor of
subsequent graft failure [3, 4]. Subclinical AR has been deﬁned
as ‘the documentation by light histology of unexpected evidence
of AR in a stable patient’ and concerns 5–10% of patients without
high immunological risk. Hence, most transplant centres rou-
tinely perform ‘surveillance’ transplant biopsies between 3 and
12months post-KTx. Since current immunosuppressive drugs ef-
ﬁciently treat AR, diagnosing AR early is crucial. Of note, it is still
not debated whether subclinical AR should be treated or not. Al-
though some centres treat subclinical AR, others do not compul-
sively treat it because of the lack of strong evidence about the
risk–beneﬁt balance of increased immunosuppression. In a 10-
year observational prospective cohort study of 1001 consecutive
non-selected KTRs who underwent ABO-compatible, comple-
ment-dependent, cytotoxicity-negative crossmatch KTx and
who underwent screening biopsies at 1 year, treatment of sub-
clinical T-cell-mediated AR resulted in similar long-term graft
survival as in patients without rejection [4]. In contrast, subclin-
ical antibody-mediated AR detected at the 1-year screening bi-
opsy carried a negative prognostic value independent of initial
donor-speciﬁc antibody status, previous immunologic events, es-
timated glomerular ﬁltration rate (eGFR) and proteinuria.
In clinical practice, the detection of AR critically depends on
periodic assessments of serum creatinine (SCr), an insensitive
measure of renal injury, together with clinical signs like oedema
or hypertension [5]. Ultimately, diagnosis of AR relies on trans-
plant needle biopsy. Examining kidney samples by light micros-
copy provides well-characterized and gold-standard criteria for
renal AR summarized in the conventional Banff classiﬁcation
[2, 6]. However, such an invasive procedure may cause graft
bleeding or arteriovenous ﬁstula. In addition, distinct reports
based on former pathology classiﬁcation [7] or frozen pre-im-
plantation biopsies [8] highlighted sampling error and interob-
server variability. Moreover, repeated biopsies to evaluate the
renal graft’s status pose challenges, including practicability and
cost. Therefore, alternative, less invasive but highly sensitivemo-
dalities are currently under investigation to reinforce our arma-
mentarium in the diagnosis of AR [1, 9–15]. Likewise, it would
be useful to non-invasively predict non-rejection in KTRs with
acute renal dysfunction and suspected AR in order to avoid
needless transplant biopsy. The term ‘acute dysfunction with
no rejection’ (ADNR) has been recently proposed by Kurian et al.
[16] to reﬂect such a frequent condition in which AR is suspected
on the basis of clinical and biological judgments, but not con-
ﬁrmed by histology. The mechanisms and long-term conse-
quences of ADNR remain unknown.
In the present review, we summarize the current literature
about non-invasive approaches for the diagnosis of AR in KTRs,
with a particular emphasis on in vivo imaging methods. The ben-
eﬁts and limitations of gene expression proﬁling and omic ana-
lyses of blood and urine samples in the non-invasive diagnosis
of renal AR are reviewed in a complementary Part II article.
Most imaging techniques exploit the fact that blood ﬂow is sig-
niﬁcantly lowered in case of AR-induced inﬂammation. Indeed,
AR is associated with a recruitment of activated leukocytes into
the transplant, with the release of vasoactive mediators, such
as endothelin, leukotrienes, thromboxane A2 and LG3 (C-termin-
al fragment of perlecan) [17, 18]. In addition, activated leukocytes
are characterized by an increased avidity for glucose and its radi-
olabelled analogue, 18F-ﬂuoro-deoxy-glucose (18F-FDG). Such an
accumulation of 18F-FDG is detectable by positron emission tom-
ography (PET), as demonstrated in both rat and man [15, 19].
Ultrasound
Ultrasound (US) is based on the ‘Doppler effect’, which stipulates
that US reﬂected from moving structures changes its frequency.
The main advantages of US include rapidity and the absence of
radiation or injections of nephrotoxic contrast agent. Conversely,
US is highly operator dependent and the interpretation may be
signiﬁcantly inﬂuenced by extra-renal factors, such as age,
body mass index, atherosclerosis and arterial stiffness. In severe
AR, duplex colour Doppler US shows a spectral waveform in
which the diastolic arterial ﬂow is decreased (Figure 1) [20]. Con-
sequently, evaluation of the renal transplant resistance index (RI)
may help detect acute graft dysfunction [21–23]. However, RI
measurements cannot differentiate AR fromacute tubular necro-
sis (ATN), calcineurin inhibitor toxicity, renal vein thrombosis,
ureteral obstruction or pyelonephritis [22]. In case of delayed
graft function (DGF) [24], sequential Doppler US does not help
speciﬁcally detect AR. In 2014, Shebel et al. [25] suggested that
power Doppler may distinguish ATN with preserved cortical per-
fusion from AR with reduced perfusion. Power Doppler is based
Fig. 1. Representative Doppler ultrasound imaging in case of biopsy-proven renal allograft acute rejection. Doppler ultrasound images of a renal allograft (from the same
kidney transplant recipient) (A) without versus (B) with biopsy-proven acute rejection (AR). The index of resistance (IR; normal value <0.70) of renal parenchyma is
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on the amplitude of the Doppler signal to detect moving matter.
This procedure is independent of ﬂowdirection—thereby exclud-
ing signal aliases—and is independent of angle—thereby allow-
ing detection of smaller velocities than colour Doppler [23, 26,
27]. The role of powerDoppler in the diagnosis ofAR remains con-
troversial [28, 29] and additional investigations are required to as-
sess its sensitivity/speciﬁcity and predictive values (Table 1).
Molecular imaging techniques speciﬁcally targeting T-lym-
phocytes represent another promising tool for the detection of
AR. Grabner et al. [30] recently performed a study using anti-
body-mediated contrast-enhanced US (CEUS) using microbub-
bles targeting CD3-, CD4- or CD8-positive T-cells in various
murinemodels of kidney diseases. The results of CEUS correlated
with histopathological scoring of rejection, CD3 immuno-signal
and mRNA expression levels of chemoattractant cytokines.
Signal intensities reﬂected the degree of inﬂammation in the
allograft as early as 2 days after KTx. Conversely, ATN and CSA
toxicity were not associated with increased CEUS signals. Thus,
CD3-mediated CEUS may help speciﬁcally detect renal AR.
Further preclinical and clinical studies are warranted to assess
the diagnostic yield of CEUS in real-life settings since infection-
induced inﬁltration of T-lymphocytes may represent an import-
ant confounding factor [30].
Computed tomography
Computed tomography (CT) uses X-rays to create pictures of
cross sections of the body. Perfusion techniques are based on
the injection of iodinated contrast agents (Table 1). In 2013,
Helck et al. [31] retrospectively suggested that studying perfusion
of kidney allografts by CT may help non-invasively differentiate
AR from ATN. Twenty-two patients with either AR (n = 6) or
ATN (n = 16) were included. There was no signiﬁcant difference
regarding SCr levels between groups. All patients underwent a
multiphase CT angiography, which showed that renal blood
ﬂowvalueswere signiﬁcantly lower in allografts with biopsy-pro-
ven AR (48.3 ± 21 mL/100 mL/min) in comparison to those with
ATN (77.5 ± 21 mL/100 mL/min) [32]. Themean effective radiation
dose of the CT perfusion protocol was 13.6 ± 5.2 mSv. Further in-
vestigations are necessary to assess the clinical relevance of this
quantitative perfusion technique in discriminating the various
causes of acute graft dysfunction, taking into account the radi-
ation exposure and the risk of contrast-induced nephropathy
(which promotes the persistence of ATN).
Magnetic resonance imaging
Magnetic resonance imaging (MRI) derives from the radiofre-
quency signal generated byhydrogen atomsplaced in an external
magnetic ﬁeld. The main advantages of contrast-enhanced MRI
after infusion of gadolinium-based agents include high-contrast
resolution and the absence of ionizing radiation. KTRs with bi-
opsy-provenAR showa lower cortical enhancementwith delayed
renal excretion (Table 1). Many reports have qualitatively evalu-
ated the shape of the renal enhancement curve to diagnose
acute dysfunction. As early as 1997, Szolar et al. [33] performed
a study including 23 patients with clinically suspected ATN or
AR and 8 consecutive control patients, who underwentMR perfu-
sion imaging of renal allograft. The increase in cortical signal in-
tensity was signiﬁcantly smaller in patients with AR (61 ± 4%
increase above baseline) compared with that measured in nor-
mal allografts (136 ± 9% increase above baseline) and patients
with ATN (129 ± 3% increase above baseline) [33–38]. It should
be noted, the administration of gadolinium-based contrast
agents has been associated with nephrogenic systemic ﬁbrosis,
a devastating ﬁbrosing disorder of the skin and other systemic or-
gans. Their use is therefore prohibited in patients with acute kid-
ney injury (AKI) or stage 4/5 chronic kidney disease, as well as in
KTRs [39, 40].
Innovative applications of MRI avoiding gadolinium-based
agents have been recently developed (Table 1). Diffusion-
weighted imaging (DWI) provides quantiﬁcation of the Brownian
motion ofwater protons by calculating the apparent diffusion co-
efﬁcient (ADC) [41–44]. Several studies have shown that ADC in
patients with stable renal function is signiﬁcantly higher than
in patients with kidney dysfunction [41, 42, 44]. The diagnostic
accuracy of ADC evaluation in detecting acute renal allograft dys-
function is high, although the speciﬁcity in AR diagnosis is low
[41–43]. Indeed, ADC can be lowered in various conditions, like
ATN, drug toxicity and ischaemia [41, 42, 44]. Arterial spin label-
ling (ASL) is another non-invasive functional MRI approach that
allows one to quantify renal perfusion without administration
of contrast agents by labelling water protons of the arterial
blood with radiofrequency pulses [45]. A recent study conducted
by Hueper et al. [45] demonstrated that renal perfusion was sig-
niﬁcantly reduced in patients with DGF. Forty-six patients under-
went contrast-free ASL MRI 4 to 11 days after KTx. Renal biopsies
were performed within 5 days of MRI. Twenty-six of 46 patients
developed DGF. Of these, nine patients had biopsy-proven AR.
Renal perfusion was signiﬁcantly lower in the DGF group com-
pared with the control group (231 ± 15 versus 331 ± 15 mL/min/
100 g). Renal perfusion signiﬁcantly correlated with eGFR, RI
and cold ischaemia time. Note that ASL is not available in routine
clinical practice. Finally, blood oxygenation level-dependent
(BOLD) imaging uses deoxygenated haemoglobin as an endogen-
ous contrast agent. When the blood concentration of deoxyhe-
moglobin increases, the T2* relaxation time of the protons
decreases, which increases dephasing in the surrounding tis-
sues. R2* corresponds to 1/T2*, and is an index of the signal loss
rate [40, 46–50]. Decreased R2* values in the renal medulla corres-
pond to increased oxygen concentration. Hence, BOLD imaging
may help differentiate AR from ATN [43–45, 51]. Han et al. [34]
showed that allograftswith ATNhave decreased oxygen bioavail-
ability in early stages. Eighty-two patients with normal graft
function and 28 patients with biopsy-proven AR (n = 21) or ATN
(n = 7) were enrolled. Patients with AR and ATN underwent
BOLD MRI within 6 days before or after kidney transplant biopsy.
The mean cortical R2* level was signiﬁcantly higher in the ATN
group (15.25 ± 1.03/s) compared with the normal group (13.35 ±
2.31/s) and the AR group (12.02 ± 1.72/s). However, such an obser-
vation was not conﬁrmed by Djamali et al. [52], most probably be-
cause of the complex deﬁnition of ATN stages [51]. Furthermore,
oxygenation is dynamic and may be inﬂuenced by a number of
local and systemic stimuli, including drugs [46–49, 51].
Besides these innovative MRI applications based on en-
dogenous contrast materials, ultrasmall superparamagnetic
iron oxide (USPIO)-enhanced dynamic MRI tracks macrophage
accumulation in various tissues and organs, including kidney
transplant (Table 1). In vivo experimental USPIO studies have
been performed in rats. USPIO particles are trapped by macro-
phages through absorptive endocytosis, which creates MR sig-
nal reduction in T2*-weighted images [53–57]. Although
sensitive, USPIO-enhanced dynamic MRI is characterized by
poor speciﬁcity since image hypointensity may result from
sources other than labelled cells [53–55]. Moreover, itmay be dif-
ﬁcult to differentiate AR from infection or ischaemic injury,
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Renal scintigraphy
Planar scintigraphy detects, with a γ camera, the distribution of
radioactivity after administration of a γ photon-emitting radio-
pharmaceutical agent (Table 1). Single photon emission com-
puted tomography (SPECT) intrinsically offers high intrinsic
activity due to (i) the signiﬁcant tissue penetration of convention-
al tracers, (ii) the ability to detect very low accumulations of tra-
cers and (iii) the large range of available radiotracers [13, 63]. In
addition, nuclear imaging is largely operator independent and
generates three-dimensional (3D) functional images ofmetabolic
processes covering the whole organ/body (upon the technique
used). Radiotracers for renal scintigraphy are devoid of nephro-
toxicity [13, 55]. In the particular case of AR, SPECT-based ap-
proaches may detect the recruitment of activated leukocytes
into the transplant [13].
Dynamic renal scintigraphywith 99mTc-DTPA orMAG3 shows
poor speciﬁcity for AR diagnosis [21, 64–66]. Aktas et al. [36] sug-
gested that serial radionuclide imagingmayhelp distinguish par-
enchymal causes of graft failure. This retrospective study
included 32 patientswith acute renal allograft dysfunction. In pa-
tients with AR, at least two sets of serial images were obtained
after intravenous injection of 340 MBq of 99mTc-DTPA. Sensitivity
and speciﬁcity were high in the diagnosis of AR. Sensitivity was
even higher when considering the perfusion curve after the
peak (P/PL) rather than measuring the curve from start to peak
(Hilson’s PI) [59]. Indeed, the major pathophysiologic difference
between AR and ATN concerns renal blood ﬂow, which is signiﬁ-
cantly impaired in AR but relatively well-preserved in ATN [59].
Besides dynamic scintigraphy, static imaging using radiotra-
cers accumulating in renal parenchyma, like 67Ga-citrate, 125I-ﬁ-
brinogen and 99mTc-sulfur colloid, have been studied in AR.
Although comparativemeta-analysis suggested a similar speciﬁ-
city of these tracers in AR [60], 99mTc-sulfur colloid might be the
only one operational in clinical settings within the permissible
radiation dose. 67Ga-citrate accumulates in the polymorpho-
nuclear granulocytes recruited to inﬂammatory lesions, with
no differential speciﬁcity between bacterial or sterile inﬂamma-
tion and AR [60]. Iodinated ﬁbrinogen has been shown to deposit
along the vascular system and into renal interstitium in case of
AR [60, 63, 64]. In 1976, Niederle et al. [67] performed a prospective
study on 22 patients using 125I-ﬁbrinogen. The uptake of radiola-
belled ﬁbrinogen was increased in all biopsy-proven AR. Histolo-
gically, the kidneys with increased accumulation of ﬁbrinogen
showed extensive deposits of ﬁbrin in blood vessels, glomeruli,
intracapillary thrombi and interstitium [63]. However, 125I is not
suited for scintigraphic imaging, and this tracer has never been
used in routine clinical practice [60]. Finally, 99mTc-sulfur colloid
is trapped in ﬁbrin thrombosis associated with AR [9, 60]. The ac-
cumulation of 99mTc-sulfur colloid in kidney grafts is independ-
ent of renal function. Imaging after infusion of 99mTc-sulfur
colloid appeared to discriminate AR on the basis of a strictly vis-
ual scale [9]. Unfortunately, several studies using computer-as-
sisted quantiﬁcation of allograft uptake compared with the
surrounding pelvis showed conﬂicting results, with false-nega-
tive and false-positive rates thatwere toohigh tomake 99mTc-sul-
fur colloid useful in predicting renal AR in routine clinical
practice [65]. Furthermore, 99mTc-sulfur colloid does not accumu-
late in cases of AR-associated necrosis or in patients receiving
high doses of heparin [60].
Several experimental and clinical pilot trials have been per-
formed using radiolabelled white blood cells (WBCs) to detect
renal AR, with conﬂicting results [13, 63, 70]. Preclinical tests
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translational limitations (Table 1). First, labelledWBCs brieﬂy ac-
cumulate in the lungs. Second, labelling stability varies. Third,
the compound stability of the tracer and radionuclide half-life
have to be taken into account before reliablymeasuring the accu-
mulation of labelled leukocytes [13, 55]. Finally, background ac-
tivity as well as the degree of attenuation of target organ
activity may limit the interpretation [66]. In 2004, Lopes de
Souza et al. [38] used 99mTc-labelled WBCs to evaluate AR in
KTRs. This prospective study enrolled 100 KTRs. Scintigraphy de-
tected 13 of 16 biopsy-proven ARs and 4 of 5 ATNs, which corre-
sponds to a sensitivity of 81% for AR and 80% for ATN. The
speciﬁcity was 100%. The positive predictive value was 100%
and the negative predictive value was 95.1 and 98.9% for AR
and ATN, respectively. Similarly, radiolabelled monoclonal anti-
bodies directed against inﬁltrating cells have also been used.
Anti-CD3 (cytotoxic T-cells), anti-CD4 (helper T-cells), anti-
CD20 (B-cells), anti-CD25 (T- and B-cells), anti-DR (antigen-pre-
senting cells) or anti-granulocyte have been tested to assess in-
ﬂammation. Application of radiolabelled anti-CD3 or anti-CD25
might be promising in the particular settings of AR [59]. Still,
this technique may cause allergic reactions and is restricted to
intra- and perivascular antigens since antibodies do not cross
the endothelial barrier [13, 63].
Positron emission tomography
PET detects pairs of γ rays indirectly emitted by positron
emitting radionuclides, like 18F-FDG. PET/CT offers a direct 3D
co-registrationwith low-dose CTwithout administration of con-
trast medium. 18F-FDG PET/CT is routinely used for detection,
characterization, staging and follow-up of inﬂammatory pro-
cesses of various origins [71, 72]. Activated leukocytes are
indeed characterized by high metabolic activity and increased
uptake of glucose and its analogue, 18F-FDG (Table 1). Renal AR
is associated with a recruitment of activated leukocytes into the
transplant, which is the basis of the Banff classiﬁcation [6]. The
advantages of 18F-FDG-PET/CT are rapid imaging and a high
target:background ratio [72]. It can be used safely in patients
with renal function ranging from normal to mildly reduced
GFR to ESRD. In rats, the renal clearance of 18F-FDG does not cor-
relate with renal function [19]. In particular, acute kidney injury
secondary to cyclosporin exposure or ischaemia/reperfusion
(I/R) is not associated with signiﬁcant elevation in renal 18FDG
accumulation. In man, Minamimoto et al. [73] investigated the
inﬂuence of renal function on 18F-FDG distribution and uptake
in 20 normal volunteers and 20 patients with suspected renal
failure. Regions of interest were placed over 15 different regions
throughout the body, including the left kidney. No signiﬁcant
difference was observed in the renal mean standard uptake
value (SUV) between healthy volunteers and patients with
suspected renal failure. Limitations of 18F-FDG-PET/CT imaging
include its cost and availability, as well as the exposure to
radiation originating from both PET and CT procedures. Still, a
cumulative exposure dose of ∼5 mSv remains low compared
with other classical radiological exams, like thorax CT (7 mSv)
or abdomen CT (8 mSv) or coronary angiography (16 mSv) [15,
74]. The uptake of 18F-FDG is not speciﬁc for inﬂammation and
may be increased in other conditions, like tumours or infections
[71, 75]. Furthermore, physiological urinary excretion of 18F-FDG
may hamper the measurement of 18FDG uptake in the renal
parenchyma [76]. Late acquisitions may help overcome this
problem and eventually improve the background:noise ratio.
One rodent model of allogeneic KTx suggested that 18F-FDG
PET/CT non-invasively detects renal cellular-mediated AR
[19, 51]. Recently, we have prospectively shown the usefulness
of 18F-FDG PET/CT in KTRs presenting with suspected AR
prompting a transplant biopsy (Figure 2) [15]. On the basis
of 32 18FDG-PET/CTs in 31 adult KTRs, we found a positive
correlation between 18F-FDG transplant uptake (i.e. mean
SUV) and the acute composite Banff score of leukocyte inﬁltra-
tion (r2 = 0.49). The area under the receiver operating character-
istic (ROC) curve (AUC) was 0.93, with 100% sensitivity and 50%
speciﬁcity, using a mean SUV threshold of 1.6. The poor speciﬁ-
city of 18F-FDG PET/CT in detecting AR is primarily due to the
nature of the radiotracer. Although supporting a role for 18F-
FDG PET/CT in AR screening, these preliminary data raise
many unresolved issues, including (i) the dynamics of trans-
plant 18F-FDG uptake, (ii) the comparative yield of 18F-FDG
PET/CT in cellular- versus antibody-mediated AR, (iii) the pre-
dictive value of transplant 18F-FDG uptake on long-term renal
function and (iv) the yield of 18FDG-PET/CT in subclinical AR.
Grabner et al. [39] investigated the diagnostic yield of 18F-FDG-
labelled T lymphocytes in a rat model of allogenic KTx (Table 1).
The accumulation of labelled T-cells was signiﬁcantly elevated in
allografts with AR [1.07 ± 0.28% of injected dose (ID)] compared
with to native control kidneys (0.49 ± 0.18% ID). No difference
was found among native controls, CSA toxicity and kidneys
with I/R injury. To validate PET data, they showed signiﬁcant cor-
relations between imaging-based in vivomeasurements of T-cell
accumulation with autoradiography, histology and PCR quantiﬁ-
cations. The use of radiolabelled cells has several advantages,
such as higher sensitivity with a minimum radiation dose
and less urinary excretion of free 18F-FDG, which enables early
acquisition and quantiﬁcation. However, the production of
radiolabelled leukocytes in man would be laborious and time-
consuming.
Fig. 2. Representative 18F-FDG PET/CT imaging in case of biopsy-proven renal
allograft acute rejection. Positron-emission tomography (PET; left column),
computed tomography (CT; middle column) and combined PET/CT images
taken ∼180 min after intravenous administration of 18ﬂuoro-deoxy-glucose
(18FDG) are shown for one kidney transplant recipient (KTR) with normal renal
histology (upper panels) and one KTR with biopsy-proven acute rejection (AR).
The tracer, 18FDG, signiﬁcantly accumulates in the renal parenchyma in case of
AR. Note the detection of excreted 18FDG in the urinary pelvis in both normal
and pathological situations. The arbitrary scale of the standard uptake value
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Conclusions and perspectives
Renal AR remains one of the leading causes of reversible acute
dysfunction in KTRs and is an early predictor of subsequent
graft failure [3, 4]. The diagnosis and classiﬁcation of AR ultimate-
ly rely on transplant needle biopsy. Indeed, the current imaging
procedures do not differentiate AR subtypes and therefore do
not help in adjusting immunosuppressive therapies. However,
imaging may be useful in the early detection of AR, thereby
quickening and improving KTR management, as well as in the
follow-up of biopsy-proven AR subtypes. Importantly, the non-
invasive discrimination of AR from ADNR, with the highest
negative predictive value, would help avoid needless and risky
transplant biopsies. On the basis of the current literature, MRI
and 18F-FDG PET/CT appear the most promising approaches.
Nevertheless, none of these has been adopted yet in routine clin-
ical practice. Thismay be partly explained bymethodological and
ﬁnancial limitations. Standardization and validation of analysis
procedures are urgently required to assess reproducibility in pro-
spective multicentric trials. Furthermore, additional studies
should focus on the diagnostic yields of combinations of imaging
and omics methods.
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